NASDAQ:CYTO Altamira Therapeutics (CYTO) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free CYTO Stock Alerts $1.23 -0.06 (-4.65%) (As of 03:58 PM ET) Add Compare Share Share Today's Range$1.20▼$1.3050-Day Range$1.29▼$2.0052-Week Range$1.20▼$17.40Volume127,288 shsAverage Volume1.17 million shsMarket Capitalization$1.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Altamira Therapeutics alerts: Email Address Altamira Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.26) to ($3.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.26 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Altamira Therapeutics.Read more about Altamira Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.80% of the float of Altamira Therapeutics has been sold short.Short Interest Ratio / Days to CoverAltamira Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Altamira Therapeutics has recently increased by 27.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAltamira Therapeutics does not currently pay a dividend.Dividend GrowthAltamira Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CYTO. Previous Next 2.5 News and Social Media Coverage News SentimentAltamira Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Altamira Therapeutics this week, compared to 1 article on an average week.Search Interest10 people have searched for CYTO on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Altamira Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.03% of the stock of Altamira Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.91% of the stock of Altamira Therapeutics is held by institutions.Read more about Altamira Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Altamira Therapeutics are expected to grow in the coming year, from ($4.26) to ($3.16) per share.Price to Book Value per Share RatioAltamira Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Altamira Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressOptions expert shares his top option strategy for freeA 35 year old man from central Florida has stumbled on one of the best strategies we’ve seen in a long time. For the last 30 months his “Friday to Monday” trading strategy has maintained a 71% win rate on more than 350 trades. That includes multiple big time winners like 82% from Adobe… 77% from Palo Alto… But also a barrage of smaller winners like 20% from AMC… Each of which were opened on a Friday afternoon and closed the very next Monday morning. As you’ll see in his brand new video, this strange strategy has given him the ability to capture big time market moves over the weekend.Check it out, simply follow this link here. About Altamira Therapeutics Stock (NASDAQ:CYTO)Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Read More CYTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTO Stock News HeadlinesJune 4, 2024 | americanbankingnews.comAltamira Therapeutics (NASDAQ:CYTO) Shares Down 3.3% May 28, 2024 | globenewswire.comAltamira Therapeutics Provides Business UpdateMay 23, 2024 | msn.comWhat's Going On With Altamira Therapeutics Stock?May 23, 2024 | msn.comAltamira stock soars 45% on Bentrio social media postingsMay 23, 2024 | globenewswire.comAltamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalMay 1, 2024 | globenewswire.comAltamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationApril 24, 2024 | msn.comAltamira reports publication of positive results from NASAR clinical trial with BentrioApril 24, 2024 | globenewswire.comAltamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalApril 15, 2024 | finance.yahoo.comDiamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)April 12, 2024 | seekingalpha.comAltamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call TranscriptApril 12, 2024 | msn.comAltamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call TranscriptApril 10, 2024 | finance.yahoo.comAltamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsApril 4, 2024 | globenewswire.comAltamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024March 26, 2024 | finanznachrichten.deAltamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesMarch 26, 2024 | markets.businessinsider.comCrude Oil Moves Higher; US New Home Sales Fall In FebruaryMarch 25, 2024 | msn.comWhy Altamira Therapeutics Stock Is Racing HigherMarch 25, 2024 | msn.comAltamira stock rallies 44% on Univercells mRNA collaborationMarch 25, 2024 | globenewswire.comAltamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesFebruary 7, 2024 | finance.yahoo.comAltamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalJanuary 24, 2024 | marketwatch.comAltamira Therapeutics Shares Rise 13% After Filing Second Provisional Patent ApplicationJanuary 24, 2024 | msn.comAltamira Therapeutics stock jumps 7% as it files for second patentJanuary 24, 2024 | finance.yahoo.comAltamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentJanuary 8, 2024 | finance.yahoo.comAltamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitDecember 29, 2023 | finance.yahoo.comAltamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementDecember 11, 2023 | msn.comAltamira shares sink over 40% on corporate, stock split updatesSee More Headlines Receive CYTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/14/2024Next Earnings (Estimated)7/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTO CUSIPN/A CIK1601936 Webwww.aurismedical.com Phone(441) 295-5950Fax41-61-201-1351Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$320,000.00 Price / Sales6.07 Cash FlowN/A Price / Cash FlowN/A Book Value$4.56 per share Price / Book0.27Miscellaneous Outstanding Shares1,580,000Free Float1,372,000Market Cap$1.94 million OptionableNot Optionable Beta1.81 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Thomas Meyer Ph.D. (Age 56)Founder, President, Chairman, CEO & MD Comp: $569.7kMr. Marcel Gremaud CPA (Age 65)Chief Financial Officer Dr. Covadonga Paneda (Age 50)Chief Operating Officer Dr. Samuel A. Wickline M.D. (Age 71)Chief Scientific Adviser Key CompetitorsGraybug VisionNASDAQ:GRAYNuCanaNASDAQ:NCNAObsEvaNASDAQ:OBSVOragenicsNYSE:OGENShuttle PharmaceuticalsNASDAQ:SHPHView All Competitors CYTO Stock Analysis - Frequently Asked Questions How have CYTO shares performed in 2024? Altamira Therapeutics' stock was trading at $3.48 on January 1st, 2024. Since then, CYTO stock has decreased by 64.7% and is now trading at $1.23. View the best growth stocks for 2024 here. Are investors shorting Altamira Therapeutics? Altamira Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 128,800 shares, an increase of 27.4% from the May 15th total of 101,100 shares. Based on an average daily trading volume, of 1,920,000 shares, the short-interest ratio is currently 0.1 days. Approximately 5.8% of the shares of the company are short sold. View Altamira Therapeutics' Short Interest. When is Altamira Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our CYTO earnings forecast. When did Altamira Therapeutics' stock split? Altamira Therapeutics shares reverse split on Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Altamira Therapeutics' major shareholders? Altamira Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Altamira Therapeutics? Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTO) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altamira Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altamira Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.